Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NY:AZN)

178.75 -3.53 (-1.94%)
Official Closing Price Updated: 7:00 PM EDT, Jun 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,394,264
Open 182.52
Bid (Size) 178.50 (100)
Ask (Size) 181.50 (300)
Prev. Close 182.28
Today's Range 178.59 - 182.70
52wk Range 174.60 - 212.71
Shares Outstanding N/A
Dividend Yield 0.52%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
From AstraZeneca
Via Business Wire
News headline image
IXUS vs. IEFA: Which International ETF Is Better for Most Investors? ↗
When buying international ETFs, owning more stocks in more countries might be a better bet. 
Via The Motley Fool
Topics ETFs

Performance

YTD
-5.1%
-5.1%
1 Month
-3.1%
-3.1%
3 Month
-7.1%
-7.1%
6 Month
-5.1%
-5.1%
1 Year
-5.1%
-5.1%

More News

Read More
News headline image
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
From AstraZeneca
Via Business Wire
AstraZeneca (NYSE:AZN) Passes the Caviar Cruise Quality Screen with Strong Profitability and Growth ↗
Via Chartmill
News headline image
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
From AstraZeneca
Via Business Wire
News headline image
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
From AstraZeneca
Via Business Wire
News headline image
Marathon Halves Its Copa Stake—The Panama Hub Advantage Still Stands ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
From AstraZeneca
Via Business Wire
News headline image
3 International ETFs for Investors Looking Beyond U.S. Stocks ↗
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade ↗
Via MarketBeat
Topics Credit Cards ETFs Economy
News headline image
BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
From AstraZeneca
Via Business Wire
News headline image
M&G Shaved 2.4% of Methanex After a Near-Doubling ↗
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer
From AstraZeneca
Via Business Wire
News headline image
Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial
From AstraZeneca
Via Business Wire
News headline image
This Low-Cost ETF Holds Almost 8,800 Stocks Across Both Developed and Emerging Markets. Here's Why It's a Compelling Long-Term Core Holding ↗
Via The Motley Fool
Topics ETFs
News headline image
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat ↗
Via MarketBeat
News headline image
TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca results: Q1 2026
From AstraZeneca
Via Business Wire
News headline image
BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older
From AstraZeneca
Via Business Wire
News headline image
SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus
From AstraZeneca
Via Business Wire
News headline image
Is Bristol Myers Squibb the Best Bargain in Big Pharma? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD
From AstraZeneca
Via Business Wire
News headline image
Pictet Loads Up MercadoLibre With 3,500 Shares Worth $6.8 Million ↗
Via The Motley Fool
News headline image
Could AbbVie Crash Lilly's Weight‑Loss Party? ↗
Via The Motley Fool

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?
Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.
What exchange does AstraZeneca PLC - American Depositary Shares trade on?
AstraZeneca PLC - American Depositary Shares trades on the New York Stock Exchange
What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?
The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the New York Stock Exchange
What is the current price of AstraZeneca PLC - American Depositary Shares?
The current price of AstraZeneca PLC - American Depositary Shares is 178.75
When was AstraZeneca PLC - American Depositary Shares last traded?
The last trade of AstraZeneca PLC - American Depositary Shares was at 06/12/26 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.